RVX_logo_RGB.jpg
Resverlogix Announces US$6 Million Debenture Financing
May 05, 2021 10:01 ET | Resverlogix Corp
CALGARY, Alberta, May 05, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that it has entered into an investment agreement with a subsidiary of...
Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease
April 27, 2021 13:41 ET | Resverlogix Corp
CALGARY, Alberta, April 27, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Effect of Apabetalone...
RVX_logo_RGB.jpg
Apabetalone’s Positive Impact on COVID-19 in Human Lung Cells Published in Biomedicines
April 20, 2021 08:00 ET | Resverlogix Corp
CALGARY, Alberta, April 20, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today the publishing of an article titled: “Bromodomain and extraterminal protein...
RVX_logo_RGB.jpg
加拿大卫生部授权Resverlogix立即开始Apabetalone治疗新冠肺炎的临床研究
April 12, 2021 09:06 ET | Resverlogix Corp
阿尔伯塔省卡尔加里, April 12, 2021 (GLOBE NEWSWIRE) -- Resverlogix...
RVX_logo_RGB.jpg
加拿大衛生部向 Resverlogix 發出授權以開始對 Apabetalone 進行 2019 冠狀病毒病的即時臨床研究
April 12, 2021 09:06 ET | Resverlogix Corp
亞伯達省卡加利, April 12, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp.(「Resverlogix」)(TSX:RVX) 欣然宣佈已成功收到加拿大衛生部的「不反對書」。當局已批准 apabetalone 的 2019 冠狀病毒病臨床試驗申請。計劃的第 2 期試驗將是一項開放標籤研究、評估口服 apabetalone 的安全性和療效,以及結合...
RVX_logo_RGB.jpg
Health Canada Issues Resverlogix Authorization to Begin Immediate Clinical Studies of Apabetalone for COVID-19
April 12, 2021 08:00 ET | Resverlogix Corp
CALGARY, Alberta, April 12, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that it has successfully received its desired “No Objection Letter” from...
RVX_logo_RGB.jpg
Apabetalone’s Beneficial Effects on COVID-19 Published in Prestigious Scientific Journal Cell
March 17, 2021 08:00 ET | Resverlogix Corp
CALGARY, Alberta, March 17, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today the publishing of an article, titled: “BET Inhibition Blocks Inflammation-Induced...
RVX_logo_RGB.jpg
Apabetalone Treatment Prevents COVID-19 Infection of Human Lung Cells
March 15, 2021 10:34 ET | Resverlogix Corp
CALGARY, Alberta, March 15, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today the publishing of a new article titled: “Bromodomain and extraterminal protein...
RVX_logo_RGB.jpg
Resverlogix Announces Change in Fiscal Year-End to December 31
March 12, 2021 16:30 ET | Resverlogix Corp
CALGARY, Alberta, March 12, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) today announces that it is changing its fiscal year-end to December 31, from its...
RVX_logo_RGB.jpg
New Published Evidence of Apabetalone’s Beneficial Effects on COVID-19
March 03, 2021 08:00 ET | Resverlogix Corp
CALGARY, Alberta, March 03, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) and QIMR Berghofer Medical Research Institute (“QIMR Berghofer”), one of Australia’s most successful...